Keith Morrison
Allschwil, BL, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis.
Journal: The Journal of pharmacology and experimental therapeutics
Published: June 15, 2024
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold.
Journal: Journal of medicinal chemistry
Published: February 13, 2024
Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases.
Journal: Journal of medicinal chemistry
Published: February 13, 2024
Tribute to Paul M. Vanhoutte, MD, PhD (1940-2019).
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: November 27, 2019
Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery.
Journal: The Journal of pharmacology and experimental therapeutics
Published: November 15, 2017
Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties.
Journal: Pharmacology research & perspectives
Published: August 30, 2017
The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat.
Journal: Pharmacology research & perspectives
Published: May 12, 2017
Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential.
Journal: The Journal of pharmacology and experimental therapeutics
Published: December 21, 2016
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Journal: Journal of medicinal chemistry
Published: August 21, 2015
Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
Journal: The Journal of pharmacology and experimental therapeutics
Published: August 25, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026